Neyssa Marina
Academic Appointments
- Professor - Med Center Line, Pediatrics - Hematology & Oncology
- Member, Child Health Research Institute
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Pediatric Hematology-Oncology 725 Welch Rd MC 5798 Palo Alto, CA 94034 Tel Work (650) 497-8953 Fax (650) 497-8959Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5535Alternate Contact Stephanie Colombo Administrative Assistant Email Tel Work 650-723-5535Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Soft Tissue Sarcoma
- sarcomas
- Oncology (Cancer), Pediatric
- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Pediatric Hematology-Oncology
Administrative Appointments
- Director, Pediatric Hematology-Oncology Fellowship Program, Stanford University (2000 - 2008)
- Director of Hematology-Oncology Outpatient Clinic, Lucile Packard Children's Hospital (2000 - present)
- Associate Chief of Clinical Affairs, Pediatric Hematology-Oncology, Lucile Packard Children's Hospital (2006 - 2011)
Honors and Awards
- Alfa Omega Alfa Honor Society, Alfa Omega Alfa (1982)
- Phi Kappa Phi Honor Society, Phi Kappa Phi (1979)
- Magna Cum Laude-Antoine Lavoiser Chemistry Award, University of PR, Mayaguez Campus (1979)
Professional Education
| Internship: | University Pediatric Hospital, Puerto Rico (1984) |
| Residency: | University Pediatric Hospital, Puerto Rico (1986) |
| Board Certification: | Pediatric Hematology-Oncology, American Board of Pediatrics (1990) |
| Fellowship: | St. Jude Children's Research Hospital TN (1989) |
| Medical Education: | University of Puerto Rico, Puerto Rico (1983) |
| BS: | University of PR, Mayaguez, Chemistry (1979) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
The main focus of my research is the development of new treatment strategies for patients with bone sarcoma.
Clinical Trials
- Not Recruiting MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
- Not Recruiting Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Recruiting Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
- Not Recruiting Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
- Not Recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Publications
- A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Blood Cancer. 2013; (3): 409-14
- Changes in Health Status Among Aging Survivors of Pediatric Upper and Lower Extremity Sarcoma: A Report From the Childhood Cancer Survivor Study. Arch Phys Med Rehabil. 2013
- Children's Oncology Group's 2013 blueprint for research: Bone tumors. Pediatr Blood Cancer. 2013; (6): 1009-15
- Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2013
- Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy. Cancer Nurs. 2012 Jan-Feb; (1): 19-28
- Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012; (18): 4597-605
Help
Trial Administration